ADIPEX-P® is indicated only as short-term monotherapy for the anagement
of exogenous obesity. The safety and efficacy of combination therapy
with phentermine and any other drug products for weight loss, including
selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline,
fluvoxamine, paroxetine), have not been established. Therefore,
coadministration of these drug products for weight loss is not
recommended.
Primary Pulmonary Hypertension (PPH) - a rare,
frequently fatal disease of the lungs - has been reported to occur in
patients receiving a combination of phentermine with fenfluramine or dexfenfluramine.
The possibility of an association between PPH and the use of
phentermine alone cannot be ruled out; there have been rare cases of
PPH in patients who reportedly have taken phentermine alone. The
initial symptom of PPH is usually dyspnea. Other initial symptoms
include: angina pectoris, syncope or lower extremity edema. Patients
should be advised to report immediately any deterioration in exercise
tolerance. Treatment should be discontinued in patients who develop new, unexplained symptoms of dyspnea, angina pectoris, syncope or lower extremity edema.
Valvular Heart Disease:
Serious regurgitant cardiac valvular disease, primarily affecting the
mitral, aortic and/or tricuspid valves, has been reported in otherwise
healthy persons who had taken a combination of phentermine with
fenfluramine or dexfenfluramine for weight loss. The etiology of these
valvulopathies has not been established and their course in individuals
after the drugs are stopped is not known. The possibility of an
association between valvular heart disease and the use of phentermine
alone cannot be ruled out; there have been rare cases of valvular heart
disease in patients who reportedly have taken phentermine alone.
Tolerance
to the anorectic effect usually develops within a few weeks. When this
occurs, the recommended dose should not be exceeded in an attempt to
increase the effect; rather, the drug should be discontinued.
ADIPEX-P®
may impair the ability of the patient to engage in potentially
hazardous activities such as operating machinery or driving a motor
vehicle; the patient should therefore be cautioned accordingly.
See full Adipex-p diet pill review here
source: Adipex-P® manufacturer - http://www.gatepharma.com/Adipex-P/adipexscript.pdf
Tags: adipex-p, adipex, adipex-p warnings
Related entries:
Last update: 2008-05-09 12:57
Author:
Revision: 1.37
You can comment on this entry